Beam Therapeutics Inc.

NasdaqGS:BEAM Stock Report

Market Cap: US$2.3b

Beam Therapeutics Past Earnings Performance

Past criteria checks 0/6

Beam Therapeutics's earnings have been declining at an average annual rate of -5%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 74.4% per year.

Key information

-5.0%

Earnings growth rate

32.5%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate74.4%
Return on equity-18.1%
Net Margin-41.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation

Dec 20
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch

Nov 07

Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price

Oct 28
Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price

Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not A Buy

Sep 29

We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

Sep 04
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares

Jul 12
Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares

Beam Therapeutics: Slow Developmental Progress, But Promising Potential

Jul 01

We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

May 13
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects

Apr 24

Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S

Apr 07
Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S

Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 01
Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade

Feb 29
Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade

Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now

Feb 08

This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year

Nov 01
This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year

We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely

Jul 23
We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely

Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation

Apr 08
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation

Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts

Nov 08
Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts

Beam Therapeutics: Now Is Not The Right Time To Own

Sep 15

Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M

Aug 09

Beam drops 19% as FDA issues clinical hold on blood cancer candidate

Aug 01

Revisiting Beam Therapeutics Among Collaborative Catalysts

Jul 10

Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts

May 10
Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts

Beam Therapeutics Worth Watching Because Of Pfizer Interest?

Apr 21

Beam Therapeutics: Getting More And More Interesting

Apr 10

Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Mar 03
Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 02
Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates

Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy

Jan 19

Beam Therapeutics: An Early Company In A Promising Field

Dec 27

Revenue & Expenses Breakdown

How Beam Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:BEAM Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24350-1441260
30 Jun 24353-1431250
31 Mar 24361-1351200
31 Dec 23378-1331170
30 Sep 2382-314960
30 Jun 2380-327930
31 Mar 2377-316920
31 Dec 2261-289880
30 Sep 2292-315830
30 Jun 2277-234770
31 Mar 2260-238660
31 Dec 2152-371570
30 Sep 211-401480
30 Jun 210-408400
31 Mar 210-366330
31 Dec 200-196300
30 Sep 200-132270
30 Jun 200-119250
31 Mar 200-106230
31 Dec 190-91210
30 Sep 190-86180
30 Jun 190-134150
31 Mar 190-124130
31 Dec 180-117120

Quality Earnings: BEAM is currently unprofitable.

Growing Profit Margin: BEAM is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BEAM is unprofitable, and losses have increased over the past 5 years at a rate of 5% per year.

Accelerating Growth: Unable to compare BEAM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BEAM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: BEAM has a negative Return on Equity (-18.15%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 07:58
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Beam Therapeutics Inc. is covered by 25 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Evan SeigermanBMO Capital Markets Equity Research
Konstantinos BiliourisBMO Capital Markets Equity Research